Promising New/Novel BCMA-Targeted Treatment Options for Patients With Late Relapsed, Refractory Multiple Myeloma

Download these slides to review expert insights on available treatments for patients with late relapsed, refractory MM.

This slideset is intended for clinicians practicing medicine outside of the United States.

person default
Paula Rodriguez-Otero, MD, PhD
Format: Microsoft PowerPoint (.ppt)
File Size: 2.67 MB
Released: July 16, 2020

Acknowledgements

Provided by Clinical Care Options, LLC, in partnership with Clinical Care Options Global B.V.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
GlaxoSmithKline

Related Content

Analysis of key studies in hematologic malignancies from ASCO 2021 presented by Drs. Ian Flinn, Shaji Kumar, and Eunice Wang, as reported by Clinical Care Options (CCO)

Ian W. Flinn, MD, PhD Shaji K. Kumar, MD Eunice S. Wang, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: September 13, 2021 Expired: September 12, 2022

Gain key clinical insights from Sagar Lonial, MD on anti-BCMA ADCs for R/R MM, from Clinical Care Options (CCO)

Sagar Lonial, MD Released: September 10, 2021

Gain key clinical insights from Suzanne Lentzsch, MD, PhD on anti-BCMA bispecific antibodies for R/R MM, from Clinical Care Options (CCO)

Suzanne Lentzsch, MD, PhD Released: September 10, 2021

Gain key clinical insights from Thomas G. Martin, MD on anti-BCMA CAR T-cell therapy for R/R MM, from Clinical Care Options (CCO)

Thomas G. Martin, MD Released: September 10, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue